Buying its own future output: the company is spending now to own more of the value it already helps create
The model's full reasoning — Q1 2023 call → NOWe need to determine if management describes the company currently moving itself up or down its own value chain, taking ownership of a step previously done by others, and that this is already being executed and changing what the company earns or can do. Let's analyze the transcript. The CEO discusses several businesses: manufacturing facility, Nebula Genomics, esophageal cancer test, Linebacker, CLIA lab, etc. Key points: - Manufacturing facility: They have a manufacturing facility that is at capacity, with demand. They are building out additional capacity. They mention that they originally kept this business to maintain infrastructure and distribution, but now it's growing. They are manufacturing for other brands? Actually, they say "some of the largest brands in the world are coming to us and want us to do their manufacturing." So they are a contract manufacturer? That's not taking over a step from others; they are providing a service. They are not moving up/down their own chain; they are expanding their manufacturing business. They are not internalizing something they previously outsourced. They already had the facility. So that's not it. - Nebula Genomics: They are waiting for validations to process specimens in-house. Currently they process specimens abroad. They say: "We cannot aggressively build a B2B business until we are processing these specimens in-house." So they are currently outsourcing the sequencing? They are bringing it in-house. That is a move to internalize a step (whole genome sequencing) that they previously sent abroad. They are building a state-of-the-art lab. They are waiting for validations. They say "We are waiting for the validations, which will take another couple of months and then we will start to build out those businesses in the second half of this year with our whole genome sequencing business. Right now, we process our specimens abroad." So they are in the process of bringing sequencing in-house. That is a move to take over a step they previously depended on others for. Is it already being executed? They have built the lab, they are waiting for validations. They are not yet processing in-house. They say "We are waiting for the validations" and "we will start to build out those businesses in the second half of this year." So it's not yet operational. It's planned, but not yet executed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
FLEX · Q1 2018 → YESThe question is about whether Flex Ltd is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows Flex is actively internalizing a previously external step in the shoe manufacturing value chain by taking ownership of automation, process redesign, and end-to-end production for Nike. Management describes this as an ongoing, real-time execution: “we’re vertically integrating technologies,” “rethinking all of the whole supply process we’re applying automation technologies,” “we’ve manufactured over 1 million pairs,” and “we took over the facility in September” for Bose, with the Nike factory transition “complete by October.” They explain the value capture: the company now keeps margin it previously paid away, controls quality, cost, supply, and timing previously constrained by a counterparty, and serves customers it could not reach through the old chain. While acknowledging the ramp is early (losses persist through Q2, breakeven expected by year-end), the move is already changing what Flex earns and can do, not merely planned or contemplated. This meets all three required elements.
XOM · Q2 2018 → YESThe question is about whether ExxonMobil is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows ExxonMobil actively internalizing logistics and supply-chain steps that previously required external partners or intermediaries. Neil Chapman explicitly states they “will get engaged in the connectivity between the Permian and our Gulf Coast refining and chemical assets,” with equity participation in logistics, the Wink terminal acquisition (closed late 2017), 11 active completion crews, and a signed letter of intent for a 1 million bpd long-haul crude pipeline. These moves are already producing results: Gulf Coast refineries are “already processing our production levels and more, capturing the benefits of disadvantaged feed cost.
KMDA · Q2 2023 → YESThe question is about whether management describes the company currently moving itself further up or down its own value chain, taking ownership of a step that someone else used to perform, and that th...YES The transcript shows management describing the 2021 acquisition of the Beaumont plasma collection center as the company's entry into U.S. plasma collection, with the explicit goal of becoming a "fully integrated specialty plasma product company." They state they are "successfully expanding" capacity at the first center (already acquired and operational) and plan to open the second in Houston in early 2024. This is presented as an active, ongoing move to internalize plasma collection that previously depended on external suppliers.